Meeting
2023 ASCO Gastrointestinal Cancers Symposium
The divergent role of the GM-CSF/GM-CSFR signaling pathway in cholangiocarcinoma and pancreatic ductal adenocarcinoma.
Authors
Yatee A. Dave
Department of Surgery, Rochester, NY;
Yatee A. Dave , Paul R. Burchard , Luis I. Ruffolo , Nicholas A. Ullman , Mary Georger , Rachel Jewell , Brian A. Belt , David Linehan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 736)
DOI
10.1200/JCO.2023.41.4_suppl.736
Abstract #
736
Poster Bd #
M3
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
A SEER-based multiethnic picture of cholangiocarcinoma in the United States pre and post the advent of gemcitabine/cisplatin.
First Author: Kabir Mody
Poster
2018 Gastrointestinal Cancers Symposium
Phase II study of copanlisib (BAY 80-6946) in combination with gemcitabine and cisplatin in advanced cholangiocarcinoma.
First Author: Rutika Jitesh Mehta
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FOENIX-CCA4: A phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor 2 (FGFR2) fusions/rearrangements.
First Author: Teresa Macarulla
Poster
2023 ASCO Breakthrough
LCK and resistance to cytotoxic chemotherapy via activating an AXL-PEAK1 signaling axis in cholangiocarcinoma.
First Author: Shohei Takaichi